Private Placement of New Shares Concluded as Part of Series A Round Valued at ¥9 Billion
TOKYO, Oct. 30, 2025 — MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MEDIROM MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), has finalized a private placement of new shares. The recipients of these shares are its President and CEO, Yoshio Uekusa, and Director, Ryo Saito. This transaction is an integral part of the previously announced Series A funding round, which has a total valuation of ¥9 billion.
Background of the Investment
MEDIROM MOTHER Labs, operating as the health technology division within the Medirom Group, has been actively pursuing the delivery of specific health guidance through its “Lav” healthcare application, in addition to the development and sales of the wearable device known as “MOTHER Bracelet”. To facilitate further business expansion, the company aims to foster prompt decision-making and a management framework that is highly responsive to market dynamics. By having the leadership team directly invest, the company seeks to enhance business accountability and intensify the motivation for growth.
Future Outlook
With the successful completion of this capital raise, MEDIROM MOTHER Labs will significantly fortify its financial foundation. The company plans to accelerate the development of advanced iterations of the “MOTHER Bracelet” wearable device and establish robust systems for introducing new products to the market. As a key entity within the Medirom Group, MEDIROM MOTHER Labs is committed to delivering innovative value in the healthcare and wellness sectors, driving sustainable growth both domestically and on an international scale.
ABOUT MEDIROM MOTHER Labs Inc.
A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), MEDIROM MOTHER Labs Inc. is dedicated to the health-tech sector. The company’s primary activities encompass the ‘Specific Health Guidance Program’ offered via the ‘Lav’ health application, as well as the creation and distribution of the 24/7 recharge-free MOTHER Bracelet smart tracker. Leveraging the distinct capabilities of the recharge-free MOTHER Bracelet, MOTHER Labs provides customizable health management solutions across various fields, including caregiving, logistics, and manufacturing, among others.
MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website:
Contact Information:
Forward-Looking Statements Regarding MEDIROM
Certain declarations within this press release constitute forward-looking statements for the purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve estimations or projections concerning MEDIROM’s potential operating results, financial health, business strategies and plans, market opportunities, competitive standing, industry environment, and prospective growth opportunities. In some instances, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other phrases that convey the inherent uncertainty of future events or outcomes. These statements relate to future occurrences or to MEDIROM’s future financial performance, and they involve known and unknown risks, uncertainties, and other factors that could cause MEDIROM’s actual results, levels of activity, performance, or achievements to diverge from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they incorporate known and unknown risks, uncertainties, and other factors that are, in certain cases, beyond MEDIROM’s control and which could, and are likely to, impact actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects MEDIROM’s current perspectives regarding future events and is subject to these and other risks, uncertainties, and assumptions pertaining to MEDIROM’s operations, results of operations, growth strategy, and liquidity. Some of the factors that could lead to actual results differing materially from those expressed or implied by the forward-looking statements in this press release include:
- MEDIROM’s capacity to meet its business development objectives and to implement and adapt its growth strategies, priorities, and initiatives;
- Fluctuations in Japanese and global economic conditions and financial markets, including their impact on MEDIROM’s expansion within Japan and select international markets;
- MEDIROM’s ability to attain and maintain profitability in its Digital Preventative Healthcare Segment;
- The volatility of foreign exchange rates, which influences MEDIROM’s expenses and liabilities payable in foreign currencies;
- MEDIROM’s ability to preserve and enhance the value of its brands and to uphold and enforce its trademarks and safeguard its other intellectual property;
- MEDIROM’s ability to secure additional capital on acceptable terms or at all;
- MEDIROM’s level of indebtedness and potential constraints placed on MEDIROM by its debt instruments;
- Changes in consumer preferences and MEDIROM’s competitive landscape;
- MEDIROM’s capacity to respond to natural calamities, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and
- The regulatory environment in which MEDIROM operates.
Further details on these risks and other potential factors that could influence MEDIROM’s business, reputation, operating results, financial status, and stock price are included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent submissions, which are accessible on the SEC website at www.sec.gov. MEDIROM disclaims any obligation to update or amend these forward-looking statements for any reason, or to update the explanations for why actual results might diverge from those projected in these statements, even if new information emerges in the future.
Accompanying images for this announcement are available here:
